NOV 28·GlobeNewswireMed
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home ...